Navigation Links
Educating the Marketplace to Support Successful Oncology Product Launches
Date:10/28/2009

CHAPEL HILL, N.C., Oct. 28 /PRNewswire/ -- The bio-pharmaceutical marketplace - and the Oncology therapeutic area in particular - continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new Oncology products are scrutinizing their strategies and tactics to support market education.

Commercial executives in the Oncology therapeutic area make clinical and compound data disclosures earlier than other therapeutic areas, according to new research from Best Practices, LLC. For instance, 40 percent of commercial Oncology leaders said they communicate mechanism of action data at pre-clinical whereas only 29 percent of the total study participants said they communicate MOA at that time, according to the study.

The report, Shaping the Marketplace to Support Successful Oncology Product Launches: Tactics for Educating KOLs, Physicians, Patients and Payers, contains a plethora of benchmark metrics on the most effective physician, payer and patient education practices conducted from clinical development through launch. The 150-page report contains almost 500 metrics to help inform launch leaders in the Oncology area on the most effective type and timing of market education practices during the full development cycle.

Download a complimentary report summary, including key metrics and sample best practices at: http://www3.best-in-class.com/rr985.htm.

The research - which includes Oncology and total benchmark class segments - attracted 34 executives and managers from 26 leading pharmaceutical, biotech and medical device companies including, GlaxoSmithKline, Novartis, Novo Nordisk, Genentech, Roche, AstraZeneca, Lilly, Abbott and Bayer. Additionally, the research reflects on nine deep-dive interviews with selected participants.


'/>"/>

SOURCE Best Practices, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Speedus Announces Compliance with Nasdaq Marketplace Rules 5250(c)(1) and 4350(b)(1)(B), and Receipt of Noncompliance Notification Related to Nasdaq Marketplace Rule 5550
2. The Worlds Only Online Marketplace Dedicated to Buying and Selling Gently Used and New Special-Needs Equipment: DifferentNeedz.com
3. American Lung Association of California Joins Sheriffs Department to Support Influenza Vaccination In Sacramento
4. NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
5. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
6. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
7. University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety
8. Latest Content Release for The T SystemEV EDIS Supports Clinicians in Providing Quality Care for H1N1 Patients
9. Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference
10. Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates
11. DATATRAK eClinical(TM) Supports Multifaceted Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)...  Bayer HealthCare and Orion Corporation, a pharmaceutical ... , have begun to enroll patients in a ... androgen receptor inhibitor in clinical development. The study, ... prostate cancer who have rising Prostate Specific Antigen ... is designed to determine the effects of the ...
(Date:9/15/2014)...  Patients in today,s changing health care landscape are ... outpatient setting versus a hospital. In an effort to ... patients continue to receive high quality medical care; Kaiser ... internal medicine residency program. The program,s progressive curriculum will ... and even virtual settings. "We are ...
(Date:9/15/2014)... and BRUSSELS , Sept. 15, 2014 ... UCB (Euronext Brussels:UCB) today announced results from several exploratory ... postmenopausal women with low bone mineral density (BMD). Romosozumab ... work by inhibiting the protein sclerostin, thereby increasing bone ... at the American Society for Bone and Mineral Research ...
Breaking Medicine Technology:Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 2Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15
... Publicis Groupe announced today that ... Healthcare Communications Group (PHCG), powerfully redefining Publicis Groupe,s ... healthcare sector. PHCG is the world,s ... Digitas Health and Razorfish Health -- Publicis Groupe,s ...
... 27, 2011 Halozyme Therapeutics, Inc. (NASDAQ: ... targeting the extracellular matrix for the diabetes, ... results from a study in patients with type 1 ... Phase 1b study was conducted as a randomized, double-blind, ...
Cached Medicine Technology:Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 2Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 3Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 4Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 5Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial 2Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial 3Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial 4
(Date:9/16/2014)... Hospital announced today it is teaming up with the ... the Presenting Sponsor of the 2014-15 and 2015-16 seasons, ... partner. As the Presenting Sponsor for the next two ... inclusion on all Lightning advertising campaigns and materials throughout ... sponsorship partner of the Lightning since 2011, and it ...
(Date:9/16/2014)... of dairy food may reduce the risk of heart ... have not traditionally formed part of the diet. ... Emeritus Professor Mark Wahlqvist from Monash University,s Department of ... considered the role increased consumption of dairy foods had ... , "In a dominantly Chinese food culture, unaccustomed ...
(Date:9/16/2014)... who have had children (parous women) appear to ... breast cancer, the subtype that carries a higher ... of African ancestry. A similar relationship was ... between childbearing and increased risk of estrogen receptor-negative ... the women who had never breastfed. These findings, ...
(Date:9/16/2014)... have developed a new cocktail that is highly ... pluripotent stem cells. , Regenerative medicine is a ... lost or damaged cells, tissues or organs through ... embryos can trigger ethical concerns, a good solution ... state using a combination of reprogramming factors. ...
(Date:9/16/2014)... Terminsurancevirginia.com has released a new blog ... life insurance for obese clients. , Obese clients ... quotes. It is unlikely for applicants to be denied ... life insurance costs. , Having life insurance is ... Life insurance is available as temporary or permanent coverage ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2Health News:Lactation linked to reduced estrogen receptor-negative, triple-negative breast cancer risk 2Health News:Scientists create therapy-grade stem cells using new cocktail to reprogram adult cells 2Health News:Obese Clients Can Find Affordable No Exam Term Life Insurance at Terminsurancevirginia.com! 2
... HealthDay Reporter , MONDAY, Feb. 7 (HealthDay News) -- ... may be less likely to develop a tough-to-treat brain ... It,s not clear how this knowledge might improve prevention ... said the findings pave the way for further research. ...
... Feb. 7 (HealthDay News) -- The number of Americans ... economy, statistics released Monday suggest. Last year, there ... country, up five percent from 2009, the American Society ... cosmetic surgical procedures and 11.6 cosmetic minimally-invasive procedures. The ...
... State for Research and Emilio Botn, president of ... Finantial City (located in Boadilla del Monte) the ... included in PESA (Progression of Early Subclinical Atherosclerosis) ... Center for Cardiovascular Research (CNIC) and Grupo Santander ...
... radiation from cardiac imaging and other procedures after a ... cancer, found a new study published in CMAJ ... only) http://www.cmaj.ca/embargo/cmaj100463.pdf . The use of procedures ... angiography and nuclear scans, is increasing which has led ...
... Geneva, Switzerland. Following the publication of several media reports ... grants financed by the Global Fund to Fight AIDS, ... all donors and governments to continue their funding. ... instrument which attracts, manages and disburses resources to prevent ...
... diseases. Gene therapy direct replacement of mutant genes by ... defects. Now a research team based at the Medical Center ... Carsten Rudolph, has taken a new approach that avoids DNA ... modification of mRNAs (the metabolically active molecules derived from genomic ...
Cached Medicine News:Health News:Allergies Linked to Lower Brain Cancer Rate in Study 2Health News:Allergies Linked to Lower Brain Cancer Rate in Study 3Health News:As Economy Picks Up, So Do Number of Nips & Tucks 2Health News:CNIC and Grupo Santander present a new venue for imaging tests included in PESA study 2Health News:CNIC and Grupo Santander present a new venue for imaging tests included in PESA study 3Health News:Risk of cancer increases with exposure to low-dose radiation 2Health News:Media reports ignore that Global Fund resources deliver tremendous results in the fight against AIDS 2Health News:Save messengers -- modified mRNAs open up new therapeutic possibilities 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: